Expression of miR-664 and miR-184 on proliferation, apoptosis and migration of osteosarcoma cells

The expression of micro-ribonucleic acid miR-664 and miR-184 on the biological characteristics of osteosarcoma (OS) SOSP-9607 cells was investigated. Eighteen surgical specimens of OS and 18 normal tissue specimens were collected. The expression of miR-664 and miR-184 was detected via fluorescence reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The OS cell line SOSP-9607 was selected as the object of study, and miR-664 blank group, miR-664 mimic group, miR-664 inhibitor group, miR-184 blank group, miR-184 mimic group and miR-184 inhibitor group were established through transfection. Changes in apoptosis were detected via flow cytometry, the cell proliferation capacity was detected via Cell Counting Kit-8 assay, and the cell migration was observed via wound healing assay. In cancer tissues of OS patients, the relative expression of miR-664 and miR-184 was significantly higher than that in para-carcinoma tissues (P<0.05). The cell growth in miR-664 inhibitor group was obviously decreased compared with those in miR-664 blank and mimic groups (P<0.05). There were differences in the cell migration capacity among groups (P<0.01), and the cell scratch areas in miR-664 and miR-184 mimic groups were significantly decreased compared with those in miR-664 and miR-184 blank groups (P<0.05), while they were significantly increased in miR-664 and miR-184 inhibitor groups compared with those in miR-664 and miR-184 blank and mimic groups (P<0.05, P<0.01). There were differences in the apoptosis rate among groups (P<0.01) and apoptosis in miR-664 and miR-184 inhibitor groups was remarkably increased compared with those in miR-664 and miR-184 blank and mimic groups (P<0.05). Downregulating the expression of miR-664 and miR-184 may promote apoptosis, inhibit the proliferation and reduce the migration capacity of SOSP-9607 cells. Therefore, miR-664 and miR-184 may provide a theoretical basis for the target selection in clinical targeted therapy and drug development for OS.

[1]  Liang Wu,et al.  MicroRNA-664 Targets Insulin Receptor Substrate 1 to Suppress Cell Proliferation and Invasion in Breast Cancer. , 2019, Oncology research.

[2]  H. Mirzaei,et al.  Circulating miR-21 as novel biomarker in gastric cancer: Diagnostic and prognostic biomarker , 2018, Journal of cancer research and therapeutics.

[3]  Yi-Song Wang,et al.  High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer. , 2018, Lung cancer.

[4]  G. Goodall,et al.  Clinical Utility of a STAT3-Regulated miRNA-200 Family Signature with Prognostic Potential in Early Gastric Cancer , 2018, Clinical Cancer Research.

[5]  Yih-Leong Chang,et al.  Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C. , 2017, Cancer letters.

[6]  M. Michael,et al.  MicroRNA Biogenesis in Hypoxia. , 2017, MicroRNA.

[7]  Fenggui Wei,et al.  MicroRNA-10b mediates TGF-β1-regulated glioblastoma proliferation, migration and epithelial-mesenchymal transition. , 2017, International journal of oncology.

[8]  A. Halim,et al.  Prognostic factors and survival rate of osteosarcoma: A single‐institution study , 2017, Asia-Pacific journal of clinical oncology.

[9]  Phillip A. Sharp,et al.  Super-Enhancer-Mediated RNA Processing Revealed by Integrative MicroRNA Network Analysis , 2017, Cell.

[10]  R. Lavker,et al.  miR‐184 exhibits angiostatic properties via regulation of Akt and VEGF signaling pathways , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  Fenggui Wei,et al.  MicroRNA-10 b mediates TGF-β 1-regulated glioblastoma proliferation , migration and epithelial-mesenchymal transition , 2017 .

[12]  D. Hawkins,et al.  Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Yong Mou,et al.  MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1 , 2016, Medical science monitor : international medical journal of experimental and clinical research.

[14]  Dongqi Li,et al.  Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment , 2016, Oncotarget.

[15]  Kazuhiro Tada,et al.  Genetic variations in interleukin-6 polymorphism and the association with susceptibility and overall survival of osteosarcoma , 2016, Tumor Biology.

[16]  Bin Chen,et al.  Overexpression of miR-664 is associated with enhanced osteosarcoma cell migration and invasion ability via targeting SOX7 , 2017, Clinical and Experimental Medicine.

[17]  P. Meltzer,et al.  Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Rohren,et al.  Alpha Emitter Radium 223 in High-Risk Osteosarcoma: First Clinical Evidence of Response and Blood-Brain Barrier Penetration. , 2015, JAMA oncology.

[19]  Xiu-chun Yu,et al.  Postoperative infection and survival in osteosarcoma patients: Reconsideration of immunotherapy for osteosarcoma. , 2015, Molecular and clinical oncology.

[20]  N. Jaffe,et al.  Recurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review , 2014, British Journal of Cancer.

[21]  I. Lewis,et al.  Osteosarcoma treatment - where do we stand? A state of the art review. , 2014, Cancer treatment reviews.

[22]  Shelly C. Lu,et al.  MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma. , 2013, The Journal of clinical investigation.

[23]  Shuang Huang,et al.  Ratio of miR-196s to HOXC8 messenger RNA correlates with breast cancer cell migration and metastasis. , 2010, Cancer research.

[24]  P. Picci.  Osteosarcoma (Osteogenic sarcoma) , 2007, Orphanet journal of rare diseases.

[25]  V. Kim,et al.  The nuclear RNase III Drosha initiates microRNA processing , 2003, Nature.

[26]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.